Published in final edited form as:

J Interv Cardiol. 2016 February ; 29(1): 89–98. doi:10.1111/joic.12269.

Circulating Endothelial Cells and Endothelial Function predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction

Abdel Hamid Magdy, MD*, Sameh Bakhom, MD*, Yasser Sharaf, MD*, Dina Sabry, MD**, Ahmed T El-Gengehe, MD, and Ahmed Abdel-Latif, MD, PhD***

*Cardiology department, Cairo University, Cairo, Egypt

**Molecular biology and Biochemistry department, Cairo University, Cairo, Egypt

***Department of Medicine, Division of Cardiology, University of Kentucky, Lexington, Kentucky, U.S.A

Abstract

Endothelial progenitor cells (EPCs) and circulating endothelial cells (CECs) are mobilized from the bone marrow and increase in the early phase after ST-elevation myocardial infarction (STEMI). The aim of this study was to assess the prognostic significance of CECs and indices of endothelial dysfunction in patients with STEMI. In 78 patients with acute STEMI, characterization of CD34⁺/VEGFR2⁺ CECs, and indices of endothelial damage/dysfunction such as brachial artery flow mediated dilatation (FMD) were determined. Blood samples for CECs assessment and quantification were obtained within 24 hours of admission and FMD was assessed during the index hospitalization. At 30 days follow up, the primary composite end point of major cardiac adverse events (MACE) consisting of all-cause mortality, recurrent non-fatal MI, or heart failure and the secondary endpoint of early adverse left ventricular (LV) remodeling were analyzed. The 17 patients (22%) who developed MACE had significantly higher CEC level ($P = 0.004$), vWF level ($P = 0.028$), and significantly lower FMD ($P = 0.006$) compared to the remaining patients. Logistic regression analysis showed that CECs level and LV ejection fraction were independent predictors of MACE. The areas under the receiver operating characteristic curves (ROC) for CEC level, FMD, and the logistic model with both markers were 0.73, 0.75, and 0.82 respectively for prediction of the MACE. The 16 patients who developed the secondary endpoint had significantly higher CEC level compared to remaining patients ($p = 0.038$). In conclusion, increased circulating endothelial cells and endothelial dysfunction predicted the occurrence of major adverse cardiac events and adverse cardiac remodeling in patients with STEMI.

Keywords

Circulating endothelial progenitor cells; Acute ST-segment elevation myocardial infarction; Endothelial dysfunction; Flow mediated dilatation; Major adverse cardiovascular events; Early adverse left ventricular remodeling

Introduction

Acute myocardial infarction (AMI) leads to tissue damage and deterioration of ventricular function over time. AMI induces a generalized inflammatory response reflected by increased plasma levels of chemoattractants leading to increased circulating CD34-positive hematopoietic stem cells (HSCs) as well as endothelial progenitor cells (EPCs). This mobilization occurs within few hours to days after the onset of AMI along with a significant increase in plasma levels of vascular endothelial growth factor.^(1,2) A study by Wojakowski et al.⁽³⁾ demonstrated that the mobilized peripheral blood mononuclear cells (MNCs) in the setting of AMI express specific cardiac, muscle, and endothelial markers. The capacity of EPCs isolated from the peripheral blood of healthy adult volunteers and patients with coronary artery disease (CAD) to transdifferentiate into cardiac myocytes when co-cultured with rat cardiomyocytes have also been reported.⁽⁴⁾ Several studies have shown that intracoronary infusion of either circulating progenitor cells or bone marrow-derived progenitor cells was associated with significant improvement in global left ventricular (LV) function, and significant reductions in LV end-systolic volumes, suggesting a favorable LV remodeling process following AMI.⁽⁵⁻⁷⁾ Levels of circulating EPCs were also found useful as a prognostic marker of cardiovascular risk and outcome. A strong correlation was detected between the number of circulating EPCs in peripheral blood samples from healthy men and their combined Framingham risk factor score.⁽⁸⁾ In a prospective study of patients with CAD, a significantly higher incidence of death from cardiovascular (CV) causes was observed in patients with low baseline levels of EPCs at the end of 1 year observational period.⁽⁹⁾ The aim of this study is to examine the prognostic role of circulating endothelial cell (CECs)/colony forming units-endothelial cells (CFU-ECs) level and indices of endothelial dysfunction in predicting major adverse CV outcomes and early adverse left ventricular remodeling (ALVR) in patients with ST-segment elevation myocardial infarction (STEMI).

Methods

Please refer to the supplemental data for detailed description of the Methods.

Study Population

A total of 85 patients with an acute STEMI (18-85 years old) were prospectively screened for inclusion in the study between July 2013 and September 2013. The study was approved by the ethics committee of Cairo University hospital and conducted in accordance with the Declaration of Helsinki. A written, informed consent was obtained from each patient. All the patients underwent either primary percutaneous coronary intervention (PCI) or IV thrombolytic therapy followed by coronary angiography within 24 hours according to the

timing of presentation and at the discretion of the treating physician. Patients received standard treatment for STEMI according to the recommendations of the American College of Cardiology Foundation guidelines.⁽¹⁰⁾

Laboratory and Echocardiography Assays

A peripheral blood (PB) sample was collected within 24 hours of admission from all patients for CECs in vitro culture and identification using flow cytometry and functional assays as well as vonWillebrand factor estimation by enzyme-linked immunosorbent assay (ELISA). Within 48 hours of admission, a baseline trans-thoracic echocardiography (TTE) was performed to calculate left ventricular (LV) end diastolic dimension (LVEDD) and volume (LVEDV), LV end systolic dimension (LVESD) and volume (LVESV), LV wall motion score index (LV WMSI), LV myocardial performance index (LV MPI) and LV ejection fraction (EF) using biplane Simpson's method. At 30-day follow up, a repeat TTE could be obtained in 62 patients.

Brachial arterial flow-mediated dilation (FMD) was performed according to the previously described protocol by Donald et al.⁽¹¹⁾

Identification and quantification of circulating endothelial cells—Peripheral blood mononuclear cells (PB-MNCs) fraction were isolated using density-gradient centrifugation with Ficoll-Paque (Gibco-Invitrogen, Grand Island, NY). PB-MNCs were cultured in endothelial culture medium (EC basal medium-2; Lonza-Walkersville, MD, USA) and incubated at 37°C with 5% CO₂ for 14 days. By day 14, cells were further characterized using capillary formation assays and flow cytometry.

Circulating endothelial cell functional assessment—Total RNA was extracted from identified human CECs and Real-time qPCR was performed to assess the expression of VEGFR-2, eNOS and GAPDH genes according to previously published methods.⁽¹²⁻¹⁴⁾

Calculation of the TIMI risk score

Clinical TIMI risk score was calculated for all enrolled patients. Full details of the design and methods of the TIMI risk score has been previously published⁽¹⁵⁾. The TIMI risk score consists of age, prior angina, diabetes, hypertension, systolic blood pressure <100 mmHg, heart rate >100 beats/minute, Killip class II to IV, weight <67 kg, anterior ST-segment elevation or left bundle branch block on electrocardiogram, and time to treatment >4 hours.

Study endpoints

At 30 days from admission, the primary composite end point of the following major adverse cardiovascular events (MACE): heart failure, recurrent non-fatal MI, or all-cause mortality and the secondary endpoint of early adverse left ventricular (LV) remodeling defined as 20% increase in the echocardiographic LVEDV compared to baseline were analyzed.

Statistical analysis

Differences between groups were assessed by unpaired 2-tailed t test and the Mann-Whitney U test for continuous variables, as appropriate. Categorical data and proportions were

analyzed by the use of chi-square or Fisher's exact test when required. We assessed predictors of the MACE and the secondary endpoint at 30-day follow-up using a binary logistic regression. All significant variables in the univariate analysis were entered into a multivariable logistic regression model, and non-significant variables were backwards eliminated. Optimal cut-off points of EPCs level and FMD percent to predict MACE were calculated using receiver-operator characteristics (ROC) analysis. Binary logistic regression was also employed to measure the predictive probabilities of the combination of EPCs level, FMD and TIMI risk score model for 30-day MACE. Comparison of the predictive accuracy with the c-statistics, a measure of the area under the receiver-operator characteristic curve, was carried out using the procedure proposed by DeLong and colleagues.⁽¹⁹⁾ P value was considered significant if less than 0.05.

Results

A total of 78 patients with acute STEMI were included in the analysis of the baseline characteristics. The mean age ($\pm$ SD) of the patients was 53.8 ± 10.6 years (range 28 – 83). More than half of the patient population had anterior STEMI and 55.1% of them were treated with successful primary percutaneous coronary intervention (PPCI). The majority of patients were clinically stable after their STEMI (85.9% Killip class I) (Table 1). The differences between patients who developed MACE and those who did not are summarized in Table 2. Overall, there were no significant differences between the two groups in the baseline characteristics and comorbidities. However, patients who developed MACE were more likely to have anterior STEMI (82% vs. 48%, $p=0.011$) and had a significantly higher TIMI risk score [6 (3-7) vs. 2 (1-3), $p<0.001$] compared to those who did not develop MACE. There was a trend towards higher peak troponin I levels in patients who developed MACE.

Clinical Study Endpoints

Seventeen patients (21.8%) out of 78 patients developed the primary clinical endpoint of the following MACE: congestive heart failure (CHF) (12 patients), recurrent non-fatal MI (1 patient), or all-cause mortality (5 patients). One patient had evidence of CHF during hospital stay and died before the 30-day follow-up visit. Patients of the MACE group had a significantly higher EPCs level ($p=0.004$), VEGFR2 gene expression ($p=0.023$), vWF level ($p=0.028$) and significantly lower FMD ($p=0.006$) compared to the non-MACE group (Table 2).

Sixteen patients (25.8%) out of 62 patients (who underwent 30 day TTE) developed ALVR. These patients had significantly higher EPCs level ($P=0.038$) compared to the rest of the patients without evidence of early ALVR (Table 3).

CD34⁺/VEGFR2⁺ circulating endothelial cell level and function

Previous studies have demonstrated that MI can lead to the mobilization of bone marrow-derived stem cells and that this mobilization correlates with the extent of injury. Patients who developed MACE had higher percentage of anterior MI and trends towards higher troponin levels. This correlated with significantly higher numbers of CECs in this population

(1.74%; IQR: 1.62 to 1.89 % vs. 1.5%; 0.52-1.76%, $p=0.004$). The increased number of CECs was also associated with significantly higher gene expression of VEGFR2 (1.02 ± 0.31 vs. 0.8 ± 0.36 , $p=0.023$). Similarly, the level of vWF was significantly higher among patients with MACE and anterior STEMI (835 ± 349 vs. 623 ± 343 ng/ml, $p=0.028$). However, we did not observe significant difference in eNOS gene expression between the two groups. This higher CECs numbers and the elevated endothelial gene expression could be related to larger myocardial injury among those who developed MACE. ROC analysis revealed that a cut-off point CEC level of > 1.64 % best predicted 30-day MACE with a sensitivity of 76.5% and a specificity of 63.9%.

Indices of Endothelial function

The level of vascular reactivity as measured by FMD of the brachial artery has been shown in multiple human studies to reflect the prognosis of patients with CAD. In our study population, FMD was significantly lower in patients who developed MACE compared to those who did not suffer MACE (3.5 ± 1.4 vs. 5.9 ± 3.1 %, $p=0.006$). ROC analysis revealed that a cut-off point FMD of 4.7 % best predicted 30-day MACE with a sensitivity of 93.3% and specificity of 63.9%.

Predictors of outcomes

The predictors of MACE at 30-day follow-up after STEMI were assessed using a binary logistic regression model that included anterior MI location, LV EF, LV MPI, LV WMSI, WBCs count, CD34⁺/VEGFR2⁺ CEC level, VEGFR2 gene expression, plasma vWF level, and FMD. Multivariable analysis showed that only LVEF ($p=0.002$) and CEC level ($p=0.019$) were the independent predictors of MACE at 30-day follow-up (Table 4).

Additive prognostic value of combined CD34⁺/VEGFR2⁺EPCs level and brachial artery FMD

The accuracy of CD34⁺/VEGFR2⁺ EPCs level and FMD test as well as the combination of both tests to predict MACE were determined by using ROC analysis. EPCs level yielded an AUC of 0.73 (95% CI: 0.61 to 0.82, $p=0.004$) with 78.2% of the cases correctly classified. As regards FMD test, the AUC was 0.75 (95% CI: 0.64 to 0.84, $p=0.003$) with 78.9% of the cases correctly classified. The predicted probability from the binary logistic model combining the 2 tests yielded an AUC of 0.82 (95% CI 0.72 to 0.90, $p<0.001$) with 80.3% of the cases correctly classified, thus exceeding that of either test alone (Table 5 and Figure 1).

Additive prognostic value of combined CD34⁺/VEGFR2⁺ CEC level and brachial artery FMD to TIMI score

By further implementation of the ROC analysis, the AUC for TIMI risk score was: 0.77 (95% CI 0.61 to 0.92, $p<0.001$), for combined TIMI risk score and CEC level: 0.89 (95% CI 0.81 to 0.97, $p=0.115$ for comparison) and for combined TIMI risk score, EPC level and FMD: the highest value of 0.92(95% CI 0.86 to 0.98, $p=0.025$ for comparison) (Table 5 and Figure 2).

Discussion

Various clinical, electrocardiographic, laboratory and echocardiographic prognostic indices have been suggested to classify patients after AMI.⁽²⁰⁻²³⁾ However, the use of a biological prognostic marker is still very appealing. The current study is the first, to investigate the prognostic potential of the combined measurement of CEC level and function together with indices of endothelial dysfunction (FMD) in patients with acute STEMI. Our study demonstrated significantly higher CEC level ($p=0.004$), and VEGFR-2 gene expression ($p=0.023$) in patients who developed MACE at 30-day follow-up compared to the non-MACE group. On the other hand, patients who developed MACE and secondary endpoints had lower endothelial function as assessed by FMD measurements. In animal models of MI, studies have suggested that EPCs stimulated by endogenous or exogenous stimuli can lead to a remarkable recovery in ventricular performance and reduction in post-MI mortality.⁽²⁴⁻²⁶⁾ In a study by Leone et al.⁽²⁷⁾, the concentration of CD34⁺ bone marrow derived stem cells was not only higher in AMI patients compared to patients with stable CAD but was also an independent predictor of global and regional improvement of LV function at the end of 1 year follow-up. We suspect that the elevated levels of CECs, vWF and VEGFR2 may be a reflection of larger myocardial infarction in patients who went on to develop MACE.

Our results were however, in agreement with a recent study by Chang et al.⁽²⁸⁾ investigating the level of EPCs in STEMI patients undergoing primary coronary angioplasty. Although the circulating level of EPCs was considerably lower in STEMI patients compared to normal subjects in their study, the patients with high EPCs ($>1.2\%$) had lower LVEF, elevated WBCs count, more advanced CHF (class III), and increased 30-day mortality than those with a low EPC level ($<1.2\%$). Similarly, patients who developed MACE in our study had a significantly lower LVEF compared to the non-MACE group (<0.001) and 70% of them had evidence of CHF. Thus, the elevated levels of CECs in our study and the study by Chang et al could be a reflection of the higher myocardial damage. The peripheral recruitment of CECs and CD34⁺ MNCs has been reported to occur in early stages following STEMI and in CHF⁽²⁹⁾ and hence the higher CEC level in the MACE group.

The angiogenic cytokine VEGF expression was also found to be enhanced as a result of an increase in the level of hypoxia-inducible factor 1 (HIF-1) as an early response to AMI.⁽³⁰⁾ A study by Shintani et al.⁽²⁾ revealed significant increase in the circulating EPCs and CD34⁺ MNCs in patients with AMI with a significant positive correlation between CD34⁺ MNC count and the plasma levels of VEGF.⁽²⁾ In our study, a significantly higher VEGFR2 gene expression was identified in the MACE group who suffered larger infarcts. By multivariable analysis, the 2 independent predictors of 30-day MACE in the current study were the CEC level and the LVEF. A greater ischemic insult in the patients who will eventually develop MACE seems to be the triggering factor for a greater recruitment of CECs. On the other hand, an impaired LV systolic function is an established marker of short and long term adverse clinical outcome after acute MI.⁽³¹⁻³³⁾ In the recent HORIZON-AMI trial, STEMI patients with impaired LVEF had significantly higher 1-year MACE compared to patients with normal LV function even after adjustment for baseline characteristics.⁽³⁴⁾

A high level of CEC does not necessarily indicate increased functional regenerative activity of these cells. *In vitro* assays demonstrate that EPCs isolated from STEMI patients with high Killip score have lower angiogenic potential compared to patients with a low Killip score and normal control subjects.⁽²⁸⁾ Therefore, a high level of CEC in patients with evidence of early ALVR may be once again a marker of a worse clinical profile and larger infarcts in these patients rather than a marker of greater regenerative capacity of these cells.

Other findings of a significantly lower FMD in the MACE compared to the non-MACE group confirm the major link between endothelial injury or dysfunction and CV outcome described in many studies.⁽³⁵⁻³⁹⁾ vWF is a critical factor for platelet aggregation and adhesion.^(40,41) In patients with non-STEMI or unstable angina pectoris, increasing plasma VWF level was found to be an independent predictor of adverse CV outcomes at 14-day, 30-day and 1year follow-up.^(42,43) In STEMI patients, the acute release of vWF was significantly higher in patients developing heart failure and in those dying within the first month after MI.⁽⁴⁴⁾

The predictive accuracy of either CEC level or FMD test for detection of 30-day MACE were both good (AUC: 0.73 and 0.75 respectively) and could correctly classify 78.2% and 78.9% of patients, respectively. Combining the results of both tests increased the accuracy to predict 30-day MACE with an AUC of 0.82 and 80.3% of patients were correctly classified. Additionally, combination of the admission CEC level and FMD to the widely accepted TIMI risk score improved its value in predicting 30-day MACE. It is important to note that the study population was small and larger studies are needed to examine the clinical prognostic value of CECs and FMD in STEMI patients. Assessment of the cost of using the combination of these two tests over conventional prognostic markers to prevent MACE should be further studied in randomized studies.

Study limitations

The main limitation of this study is the short 30-day follow-up and longer-term studies may be needed. Another limitation is the relatively small number of patients included in this single center study. The results need to be replicated in a larger that examines the prognostic value of CEC and FMD on the individual endpoints, namely all- cause mortality, recurrent nonfatal MI, or heart failure. Our quantities analysis of CECs was performed on cells cultured for 14 days. We believe this method allows us to enrich the PB-MNCs and thus allows for better assessment of CECs. The approach may explain some of the difference between our findings and other published reports.

Conclusions

This study suggests that higher CEC levels and poor endothelial dysfunction could be markers of large myocardial infarction in patients at risk of developing adverse clinical events. They could serve as prognostic markers of clinical outcomes in patients with acute coronary syndrome independent of the established conventional risk factors. Our data suggest a multi-marker approach, inclusive of CEC, is warranted to evaluate the prognosis in patients presenting with ST elevation myocardial infarction.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Dr. Abdel-Latif is supported by the University of Kentucky Clinical and Translational Science Pilot Award (UL1TR000117), the UK COBRE Early Career Program (P20 GM103527) and the NIH Grant R56 HL124266.

References

1. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari G, Ferlini M, Goffredo L, Bertolotti A, Klersy C, Pecci A, RemigioMoratti R, Tavazzi L. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. *Blood*. 2005; 105:199–206. [PubMed: 15345590]
2. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. *Circulation*. 2001; 103:2776–2779. [PubMed: 11401930]
3. Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. *Circulation*. 2004; 110:3213–3220. [PubMed: 15533859]
4. Badorf C, Brandes RP, Popp R, Rupp S, Urbich C, Aicher A, Fleming I, Busse R, Zeiher AM, Dimmeler S. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. *Circulation*. 2003; 107:1024–1032. [PubMed: 12600917]
5. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. *Circulation*. 2002; 106:1913–1918. [PubMed: 12370212]
6. Schächinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, Abolmaali ND, Vogl TJ, Hofmann W, Martin H, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction. Final one-year results of the TOPCARE-AMI Trial. *J Am Coll Cardiol*. 2004; 44:1690–1699.
7. Wollert KC, Meyer GP, Lotz J, Lichtenberg SR, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. *Lancet*. 2004; 364:141–148. [PubMed: 15246726]
8. Hill JM, Zalos G, Halcox JPJ, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. *N Engl J Med*. 2003; 348:593–600. [PubMed: 12584367]
9. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med*. 2005; 353:999–1007. [PubMed: 16148285]
10. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013; 127:e362–e425. [PubMed: 23247304]
11. Donald AE, Halcox JP, Charakida M, Storry C, Wallace SML, Cole TJ, Friberg P, Deanfield JE. Methodological Approaches to Optimize Reproducibility and Power in Clinical Studies of Flow-Mediated Dilatation. *J Am Coll Cardiol*. 2008; 51:1959–1964.
12. Pala L, Cresci B, Manuelli C, Maggi E, Yamaguchi YF, Cappugi P, et al. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial

cells: biological effects and advanced glycosylation end products modulation. *Microvasc Res.* 2005; 70(3):179–188. [PubMed: 16271941]

13. Jiang ZL, Zhu X, Diamond MP, Abu-Soud HM, Saed GM. Nitric oxide synthase isoforms expression in fibroblasts isolated from human normal peritoneum and adhesion tissues. *Fertil Steril.* 2008; 290:769–774. [PubMed: 18440510]
14. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem.* 2009; 55:611–622. [PubMed: 19246619]
15. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation – an intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation.* 2000; 102:2031–2037. [PubMed: 11044416]
16. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience of 250 patients. *Am J Cardiol.* 1967; 20:457–464. [PubMed: 6059183]
17. Kelly D, Squire LB, Khan SQ, Dhillon O, Narayan H, Ng KH, Quinn P, Davies JE, Ng LL. Usefulness of Plasma Tissue Inhibitors of Metalloproteinases as Markers of Prognosis After Acute Myocardial Infarction. *Am J Cardiol.* 2010; 106:477–482. [PubMed: 20691304]
18. Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances: Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction). *J Am Coll Cardiol.* 2010; 55:102–110. [PubMed: 19747792]
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988; 44:837–45. [PubMed: 3203132]
20. Rommel KP, Baum A, Mende M, Desch S, Gutberlet M, Schuler G, Thiele H, Eitel I. Prognostic significance and relationship of worst lead residual ST segment elevation with myocardial damage assessed by cardiovascular MRI in myocardial infarction. *Heart.* 2014; 100:1257–1263. [PubMed: 25049315]
21. Lippi, Gand; Cervellin, G. Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. *Crit Rev Clin Lab Sci.* 2014; 51:13–29. [PubMed: 24410541]
22. Regnault V, Lagrange J, Pizard A, Safar ME, Fay R, Pitt B, Challande P, Rossignol P, Zannad F, Lacolley P. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). substudy. *Hypertension.* 2014; 63:105–111. [PubMed: 24126172]
23. Dwivedi G, Janardhanan R, Hayat SA, Swinburn JM, Senior R. Prognostic value of myocardial viability detected by myocardial contrast echocardiography early after acute myocardial infarction. *J Am Coll Cardiol.* 2007; 50:327–334.
24. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkoff D, Wang J. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med.* 2001; 7:430–436. [PubMed: 11283669]
25. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Wagner M, Isner JM, Asahara T. Ischemia and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med.* 1999; 5:434–438. [PubMed: 10202935]
26. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. *Proc Natl Acad Sci U S A.* 2001; 98:10344–10349.
27. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM, Leone G, Crea F. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. *Eur Heart J.* 2005; 26:1196–1204. [PubMed: 15734770]

28. Chang HW, Leu S, Sun CK, Hang CL, Youssef AA, Hsieh YK, Yang CH, Cheng CI, Chen SM, Chen CJ, Chua S, Chang LT, Wu CJ, Yip HK. Level and value of circulating endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty: in vivo and in vitro studies. *Transl Res*. 2010; 156:251–263. [PubMed: 20875902]
29. Valgimigli M, Rigolin GM, Fucili A, Della Porta M, Soukhomovskaia O, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. *Circulation*. 2004; 110:1209–1212. [PubMed: 15249502]
30. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. *N Engl J Med*. 2000; 342:626–633. [PubMed: 10699162]
31. DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol*. 2001; 87:1035–1038. [PubMed: 11348598]
32. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. *J Am Coll Cardiol*. 2002; 39:30–36. [PubMed: 11755283]
33. Møller JE, Egstrup K, Køber L, Poulsen SH, Nyvad O, Torp-Pedersen C. Prognostic importance of systolic and diastolic function after acute myocardial infarction. *Am Heart J*. 2003; 145:147–153. [PubMed: 12514667]
34. Ng VG, Lansky AJ, Meller S, Witzendichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. *Eur Heart J Acute Cardiovasc Care*. 2014; 3:67–77. [PubMed: 24562805]
35. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature*. 1993; 362:801–809. [PubMed: 8479518]
36. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM. Predictive Value of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a Population-Based Study The Multi-Ethnic Study of Atherosclerosis. *Circulation*. 2009; 120:502–509. [PubMed: 19635967]
37. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation*. 2000; 101:948–954. [PubMed: 10704159]
38. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation*. 2000; 101:1899–1906. [PubMed: 10779454]
39. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KRA, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. *Circulation*. 2002; 106:653–658. [PubMed: 12163423]
40. Mannucci PM. von Willebrand factor: a marker of endothelial damage? *Arterioscler Thromb Vasc Biol*. 1998; 18:1359–1362.
41. Hollestelle MJ, Thinnis T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, Loskutoff DJ, van Mourik JA. Tissue distribution of factor VIII gene expression in vivo: a closer look. *Thromb Haemost*. 2001; 86:855–861.
42. Montalescot G, Philippe F, Ankri A, Vicaute E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. *Circulation*. 1998; 98:294–299. [PubMed: 9711933]
43. Montalescot G, Collet JP, Choussat R, Ankri A, Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. *Int J Cardiol*. 2000; 72:293–294. [PubMed: 10716143]

44. Collet JP, Montalescot G, Vicaud E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. *Circulation*. 2003; 108:391–394. [PubMed: 12860898]

Figure 1.

The receiver-operator characteristic curve shows the performance of endothelial progenitor cells (CEC) level, brachial artery flow mediated dilation (FMD) test and combination of both tests to detect 30-day major adverse cardiovascular events (MACE).

Figure 2.

The receiver-operator characteristic curve shows the performance of TIMI risk score and the combination of TIMI risk score and endothelial progenitor cells (CEC) level to detect 30-day major adverse cardiovascular events (MACE).

Table 1
Baseline Demographic, Clinical, Procedural, Laboratory, Indices of Endothelial Function
and Echocardiographic Data of 78 Patients with STEMI

Variable	Value
Demographics	
Age (years), mean (range)	53.8±10.6 (28-83)
Male Gender (%)	62 (79.5)
BMI (kg/m ²)	29 ± 3
Cardiovascular Risk Factors (%)	
Family history	10 (12.8)
Dyslipidemia	59 (75.6)
Hypertension	30 (38.5)
Diabetes mellitus	37 (47.4)
Smoking	41 (52.6)
Previous MI (%)	3 (3.8)
MI Location (%)	
Anterior Location	43 (55.1)
Inferior/Lateral Location	35 (44.9)
Physical Exam	
Killip Class on admission (%)	
I, II, III, IV	67 (85.9), 6 (7.7), 2 (2.6), 3 (3.8)
Reperfusion Therapy (%)	
Primary PCI	45 (57.7)
Thrombolytic therapy	33 (42.3)
Laboratory Data	
WBCs (10 ³ cells/ml)	12.5±4.4
Creatinine (mg/dl)	0.99 ± 0.34
CECs level (%), median (IQR)	1.59 (0.64-1.78)
VEGFR2 gene expression	0.85 ± 0.36
eNOS gene expression	1.26 ± 0.61
Indices of Endothelial Function	
vWF level (ng/ml)	669 ± 353
FMD (%)	5.4 ± 3.0
Echocardiographic Data	
LV EDD (cm)	5.4 ± 0.7

Variable	Value
LV EDV (ml)	84 ± 29
LV ESD (cm)	3.9 ± 0.8
LV ESV, median (IQR) (ml)	35 (26-46)
LV EF (%)	50 ± 13
LV MPI	0.69 ± 0.15
LV WMSI	1.73 ± 0.37
MACE (%)	17 (21.8)
Heart failure	12(15.4)
Recurrent non-fatal MI	1 (1.3)
All-cause mortality	5 (6.4)
Early ALVR (%)	6 (20.5)

MI: myocardial infarction; BMI: body mass index; PCI: percutaneous coronary intervention; WBCs: white blood cells; CECs: circulating endothelial cells; IQR: interquartile range; VEGFR: vascular endothelial growth factor receptor; eNOS: endothelial nitric oxide synthase; vWF: vonWillebrand factor; FMD: flow mediated dilation; LV: left ventricular; EDD: end diastolic dimensions; EDV: end diastolic volume; ESD: end systolic dimensions; ESV: end systolic volume; EF: ejection fraction; MPI: myocardial performance index; WMSI: wall motion score index; MACE: major adverse cardiovascular events, ALVR: adverse left ventricular remodeling.

Table 2
Baseline Demographic, Clinical, Procedural, Laboratory, Indices of Endothelial Function and Echocardiographic Data of Patients who Developed the Primary Composite End Point (MACE Group) in comparison with the non-MACE Group

Variable	MACE Group (N 17)	Non-MACE Group (N 61)	P Value
Demographics			
Age (years)	57 ± 14	53 ± 9	0.150
Male Gender (%)	15 (88.2)	47 (77.0)	0.312
BMI (kg/m ²)	29.5 ± 2.4	28.8 ± 2.5	0.342
Cardiovascular Risk Factors (%)			
Family history	0	10 (16.4)	0.074
Dyslipidemia	10 (58.8)	49 (80.3)	0.068
Hypertension	8 (47.1)	22 (36.1)	0.410
Diabetes mellitus	10 (58.8)	27 (44.3)	0.288
Smoking	8 (47.1)	33 (54.1)	0.607
Previous MI (%)	2 (11.8)	1 (1.6)	0.055
Anterior MI Location (%)	14 (82.4)	29 (47.5)	0.011 *
ACEI	14 (82.4)	57 (93.4)	0.157
Statins	16 (94.1)	60 (98.4)	0.328
TIMI risk score, median (IQR)	6 (3 - 7)	2 (1 - 3)	< 0.001 *
Laboratory Data			
WBCs (10 ³ cells/ml)	15.5 ± 4.1	11.7 ± 4.1	0.001 *
Troponin I (ng/ml) median (IQR)	44 (9 - 101)	19 (7- 65)	0.202
Creatinine (mg/dl)	1.09 ± 0.39	0.97 ± 0.33	0.196
CECs level(%),median (IQR)	1.74 (1.62 - 1.89)	1.5 (0.52 - 1.76)	0.004 *
VEGFR2 gene expression	1.02 ± 0.31	0.8 ± 0.36	0.023 *
vWF level (ng/ml)	835 ± 349	623 ± 343	0.028 *
eNOS gene expression	1.5 ± 0.6	1.19 ± 0.6	0.056
Indices of Endothelial Function			
FMD (%)	3.5 ± 1.4	5.9 ± 3.1	0.006 *
Echocardiographic Data			
LV EDD (cm)	5.9 ± 0.5	5.2 ± 0.7	< 0.001 *
LV ESD (cm)	4.5 ± 0.6	3.7 ± 0.8	< 0.001 *
LV EDV (ml)	93 ± 32	78 ± 26	0.042 *
LV ESV (ml)	60 (38-78)	33 (25-44)	0.001 *

Variable	MACE Group (N 17)	Non-MACE Group (N 61)	P Value
LV EF (%)	40 ± 8	53 ± 12	<0.001 *
LV WMSI	1.98 ± 0.29	1.66 ± 0.36	0.001 *
LV MPI	0.79 ± 0.16	0.66 ± 0.14	0.002 *

MI: myocardial infarction; BMI: body mass index; ACE I: Angiotensin converting enzyme inhibitors. TIMI: thrombolysis in myocardial infarction. WBCs: white blood cells; CECs: circulating endothelial cells; IQR: interquartile range; VEGFR: vascular endothelial growth factor receptor; eNOS: endothelial nitric oxide synthase; vWF: vonWillebrand factor; FMD: flow mediated dilation; LV: left ventricular; EDD: end diastolic dimensions; EDV: end diastolic volume; ESD: end systolic dimensions; ESV: end systolic volume; EF: ejection fraction; MPI: myocardial performance index; WMSI: wall motion score index.

* $P < 0.05$.

Table 3
Baseline Demographic, Clinical, Procedural, Laboratory, Indices of Endothelial Function and Echocardiographic Data of Patients who Developed the Secondary End Point of Early Adverse LV Remodeling (ALVR Group) in comparison with the non-ALVR Group

Variable	ALVR Group (N = 16)	Non-ALVR Group (N = 46)	P Value
Demographics			
Age (years)	49 ± 10	52 ± 9	0.204
Male Gender (%)	15 (93.8)	35 (76.1)	0.123
BMI (kg/m ²)	29.4 ± 2	28.6 ± 2.4	0.221
Cardiovascular Risk Factors (%)			
Family history	4 (25)	5 (10.9)	0.167
Dyslipidemia	9 (56.2)	37 (80.4)	0.057
Hypertension	6 (37.5)	16 (34.8)	0.845
Diabetes mellitus	7 (43.8)	25 (54.3)	0.465
Smoking	11 (68.8)	23 (50)	0.194
Anterior MI Location (%)	10 (62.5)	23 (50)	0.388
ACE I	13 (81.2)	43 (93.5)	0.154
Statins	16 (100)	45 (97.8)	0.552
Laboratory Data			
WBCs (10 ³ cells/ml)	14.0 ± 3.8	11.6 ± 4.4	0.065
Troponin I (ng/ml) median (IQR)	20 (8-54)	15 (7-44)	0.605
Creatinine (mg/dl)	1.09 ± 0.40	0.94 ± 0.32	0.145
CECs level(%), median (IQR)	1.76 (1.13 - 1.89)	1.5 (0.52 - 1.74)	0.038*
VEGFR2 gene expression	0.86 ± 0.30	0.88 ± 0.39	0.892
vWF level (ng/ml)	820 ± 402	675 ± 338	0.165
eNOS gene expression	1.40 ± 0.66	1.29 ± 0.60	0.538
Indices of Endothelial Function			
FMD (%)	4.6 ± 2.9	5.7 ± 3.2	0.230
Echocardiographic Data			
LV EDD (cm)	5.5 ± 0.6	5.3 ± 0.7	0.315
LV ESD (cm)	3.9 ± 0.7	3.8 ± 0.9	0.445
LV EDV (ml)	68.7 ± 20.5	79.6 ± 25	0.129
LV ESV (ml)	33 (27-39)	33 (25-44)	0.822
LV EF (%)	50 ± 9	53 ± 13	0.490
LV WMSI	1.66 ± 0.32	1.66 ± 0.35	0.953
LV MPI	0.68 ± 0.19	0.66 ± 0.13	0.637

ALVR: Early Adverse LV Remodeling; MI: myocardial infarction; BMI: body mass index; ACE I: Angiotensin converting enzyme inhibitors. WBCs: white blood cells; CECs: circulating endothelial cells; IQR: interquartile range; VEGFR: vascular endothelial growth factor receptor;

eNOS: endothelial nitric oxide synthase; vWF: vonWillebrand factor; FMD: flow mediated dilation; LV: left ventricular; EDD: end diastolic dimensions; EDV: end diastolic volume; ESD: end systolic dimensions; ESV: end systolic volume; EF: ejection fraction; MPI: myocardial performance index; WMSI: wall motion score index.

*
 $P < 0.05$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4
Factors associated with 30-day MACE by univariate and multivariable logistic regression analysis (N=78)

Variable	Univariate Analysis				Multivariable Analysis			
	Odds Ratio	95% CI	P Value	Adjusted Odds Ratio	95% CI	P Value		
Anterior MI location	5.15	1.34 - 19.75	0.017	-	-	-	-	-
CECs CD34 ⁺ /VEGFR2 ⁺ %	4.40	1.24 - 15.61	0.022	5.43	4.14 - 7.11	0.019		
VEGFR2 gene (fold change)	6.56	1.22 - 35.12	0.028	-	-	-	-	-
vWF level	1.002	1.0001 - 1.004	0.033	-	-	-	-	-
FMD	0.66	0.49 - 0.9	0.007	-	-	-	-	-
LV EF	0.9	0.84 - 0.96	0.001	0.82	0.72 - 0.93	0.002		
LV MPI 0.68 *	3.778	1.09 - 13.04	0.036	-	-	-	-	-
LV WMSI	15.61	2.50 - 97.48	0.003	-	-	-	-	-
WBCs count	1.23	1.07 - 1.41	0.003	-	-	-	-	-

CI: confidence interval, MI: myocardial infarction; CECs: circulating endothelial cells; VEGF: vascular endothelial growth factor; vWF: vonWillebrand factor; FMD: flow mediated dilation; LV: left ventricular; EF: ejection fraction; MPI: myocardial performance index; WMSI: wall motion score index; WBCs: white blood cells.

* :median LVMPI

Table 5
Predictive accuracy of EPCs level and brachial artery flow mediated dilation test in detection of 30-day major adverse cardiovascular events

Parameter	AUC	CI 95%	P value	Correctly classified cases (%)
CECs level	0.73	0.61-0.82	0.004	78.2
FMD test	0.75	0.64-0.84	0.003	78.9
CECs level + FMD test	0.82	0.72-0.90	< 0.001	80.3
TIMI score	0.77	0.61-0.92	< 0.001	87.2
TIMI score + CECs level	0.89	0.81-0.97	< 0.001	85.9
TIMI score + CECs level + FMD	0.92	0.86-0.98	< 0.001	86.8

AUC: area under curve, CI: confidence interval, CECs: circulating endothelial cells, FMD: flow mediated dilation.